Vittoria Gebbia

Summary

Country: Italy

Publications

  1. doi request reprint Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale
    Vittorio Gebbia
    La Maddalena Clinic for Cancer, Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
    Am J Clin Oncol 33:461-4. 2010
  2. pmc Cancer patient-centered home care: a new model for health care in oncology
    Paolo Tralongo
    Medical Oncology Unit, Azienda Sanitaria Provinciale, Siracusa
    Ther Clin Risk Manag 7:387-92. 2011
  3. doi request reprint Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents
    Vittorio Gebbia
    UO Oncologia Medica, La Maddalena, Universita di Palermo, Palermo, Italy
    Expert Opin Drug Saf 11:S49-59. 2012
  4. ncbi request reprint Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma
    Vittorio Gebbia
    Medical Oncology Unit La Maddalena Cancer Clinic, via San Lorenzo Colli n 312d, 90100 Palermo, Italy
    Anticancer Res 32:529-36. 2012
  5. pmc Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Sandro Pignata
    Medical Oncology B, National Cancer Institute, Naples, Italy
    BMC Cancer 6:202. 2006
  6. ncbi request reprint Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin
    Vittorio Gebbia
    Medical Oncology Researcher, Chair of Hematology, University of Palermo, Via Alessandro Paternostro n 48, 9013 Palermo, Italy
    Crit Rev Oncol Hematol 48:S49-55. 2003
  7. ncbi request reprint Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study
    Vittorio Gebbia
    Department of Experimental Oncology, University of Palermo, Italy
    Anticancer Drugs 14:359-64. 2003
  8. ncbi request reprint Oral versus intravenous vinorelbine: clinical safety profile
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, Palermo, Italy
    Expert Opin Drug Saf 4:915-28. 2005
  9. ncbi request reprint Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, and Medical Oncology Unit, Ospedale San Giovanni di Dio, Napoli, Italy
    Clin Colorectal Cancer 5:422-8. 2006
  10. ncbi request reprint Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas
    V Gebbia
    Medical Oncology Units of the Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
    Ann Oncol 17:vii60-5. 2006

Collaborators

Detail Information

Publications41

  1. doi request reprint Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale
    Vittorio Gebbia
    La Maddalena Clinic for Cancer, Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
    Am J Clin Oncol 33:461-4. 2010
    ....
  2. pmc Cancer patient-centered home care: a new model for health care in oncology
    Paolo Tralongo
    Medical Oncology Unit, Azienda Sanitaria Provinciale, Siracusa
    Ther Clin Risk Manag 7:387-92. 2011
    ..Patient-centered home care represents an important tool to improve quality of life and help cancer patients while also being cost effective...
  3. doi request reprint Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents
    Vittorio Gebbia
    UO Oncologia Medica, La Maddalena, Universita di Palermo, Palermo, Italy
    Expert Opin Drug Saf 11:S49-59. 2012
    ....
  4. ncbi request reprint Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma
    Vittorio Gebbia
    Medical Oncology Unit La Maddalena Cancer Clinic, via San Lorenzo Colli n 312d, 90100 Palermo, Italy
    Anticancer Res 32:529-36. 2012
    ..Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens...
  5. pmc Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Sandro Pignata
    Medical Oncology B, National Cancer Institute, Naples, Italy
    BMC Cancer 6:202. 2006
    ..Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned...
  6. ncbi request reprint Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin
    Vittorio Gebbia
    Medical Oncology Researcher, Chair of Hematology, University of Palermo, Via Alessandro Paternostro n 48, 9013 Palermo, Italy
    Crit Rev Oncol Hematol 48:S49-55. 2003
    ..rhEpo also caused a positive effect on quality of life (QoL) parameters...
  7. ncbi request reprint Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study
    Vittorio Gebbia
    Department of Experimental Oncology, University of Palermo, Italy
    Anticancer Drugs 14:359-64. 2003
    ..This level of activity overlaps with the 95% CL of the activity of cisplatin alone; however, it does encourage future trials of the combination...
  8. ncbi request reprint Oral versus intravenous vinorelbine: clinical safety profile
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, Palermo, Italy
    Expert Opin Drug Saf 4:915-28. 2005
    ....
  9. ncbi request reprint Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, and Medical Oncology Unit, Ospedale San Giovanni di Dio, Napoli, Italy
    Clin Colorectal Cancer 5:422-8. 2006
    ....
  10. ncbi request reprint Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas
    V Gebbia
    Medical Oncology Units of the Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
    Ann Oncol 17:vii60-5. 2006
    ..The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer...
  11. ncbi request reprint Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials
    V Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
    Ann Oncol 16:iv123-131. 2005
  12. ncbi request reprint Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM)
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Application, University of Palermo, Italy
    Anticancer Res 26:3143-50. 2006
    ....
  13. ncbi request reprint Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
    V Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy
    Ann Oncol 18:vi124-7. 2007
    ..In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support...
  14. ncbi request reprint Cetuximab in squamous cell head and neck carcinomas
    V Gebbia
    Medical Oncology Unit, La Maddalena Hospital, Palermo, Italy
    Ann Oncol 18:vi5-7. 2007
    ..In this paper, we report a review of the major studies dealing with the use of cetuximab in advanced head and neck cancer...
  15. doi request reprint Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale)
    Vittorio Gebbia
    Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
    Lung Cancer 61:369-77. 2008
    ..The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL)...
  16. ncbi request reprint Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?
    Vittorio Gebbia
    Medical Oncology University of Palermo, Department of Experimental Oncology and Clinical Applications, Palermo, Italy
    Expert Opin Pharmacother 9:1321-37. 2008
    ..A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment...
  17. doi request reprint Evolution of therapy decision-making process for advanced non-small cell lung cancer
    Vittorio Gebbia
    Department of Experimental Oncology and Medical Applications DOSAC, University of Palermo, and Medical Oncology Division, La Maddalena Clinic for Cancer, Palermo, Italy
    Oncology 77:97-102. 2009
    ..The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment...
  18. ncbi request reprint Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma
    Vittorio Gebbia
    Institute of Clinical Medicine, University of Palermo, Italy
    Breast Cancer Res Treat 77:99-108. 2003
    ..A phase I-II trial was carried out to test the feasibility and the activity of a new bimonthly schedule of DCT...
  19. ncbi request reprint Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
    Vittorio Gebbia
    Institute of Internal Medicine, University of Palermo, Via Alessandro Paternostro n 48, 90133 Palermo, Italy
    Lung Cancer 39:179-89. 2003
    ..The primary endpoint was survival parameters, while secondary endpoints included analysis of response rates and toxicity...
  20. ncbi request reprint Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix
    Vittoria Gebbia
    Institute of Internal Medicine, University of Palermo, Palermo, Italy
    Oncology 63:31-7. 2002
    ..The main aims of the study included analysis of objective response rates, toxicity, and time to progression...
  21. ncbi request reprint Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation
    Vittorio Gebbia
    Institute of Internal Medicine, University of Palermo, Palermo, Italy
    Oncology 63:23-30. 2002
    ..Moreover, the combination of VNR and pegylated liposomal doxorubicin is active against metastatic breast carcinoma and is associated with a good toxicity profile. Further studies with this combination regimen are warranted...
  22. ncbi request reprint Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study
    Vittorio Gebbia
    Istituto Clinica Medica, University of Palermo, Palermo, Italy
    Lung Cancer 37:179-87. 2002
    ..The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival...
  23. doi request reprint First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
    Vittorio Gebbia
    Medical Oncology Unit, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy
    Lung Cancer 69:218-24. 2010
    ..The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically...
  24. pmc Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases
    V Gebbia
    Service of Chemotherapy, Institute of Pharmacology, Palermo, Italy
    Br J Cancer 68:191-4. 1993
    ..The employed regimens have been generally well tolerated. These data confirm that NPC is a neoplasm highly responsive to chemotherapy. However, duration of objective response and survival are still largely unsatisfactory...
  25. ncbi request reprint A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma
    S Palmeri
    Section of Clinical Oncology, University of Palermo, Italy
    J Chemother 3:170-5. 1991
    ..The recommended doses for a phase II study are cisplatin 20 mg/m2/week, 5-fluorouracil 400 mg/m2/week, and citrovorum factor 500 mg/m2/week...
  26. ncbi request reprint Anaemia in cancer: pathophysiology and treatment
    S Mercadante
    La Maddalena Clinic for Cancer, Palermo, Italy
    Cancer Treat Rev 26:303-11. 2000
    ..These measures are unlikely to have an effect in irreversible and progressive bleeding states...
  27. ncbi request reprint Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
    F De Vita
    Division of Medical Oncology, Second University, Napoli, Italy
    Ann Oncol 18:1354-8. 2007
    ..This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients...
  28. ncbi request reprint Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study
    S Mercadante
    Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo, Italy
    J Clin Oncol 19:2898-904. 2001
    ..To evaluate the clinical benefits of switching from morphine to oral methadone in patients who experience poor analgesia or adverse effects from morphine...
  29. ncbi request reprint Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen
    V Gebbia
    Istituto Clinica Medica, Policlinico, University of Palermo, Italy
    Ann Oncol 12:767-72. 2001
    ..In our opinion the CDDP plus VNR regimen is good enough to be compared to the anthracycline-based regimens and may represent the basis for future development of newer active polychemotherapeutic schedules...
  30. ncbi request reprint Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study
    G Cocconi
    Medical Oncology Institution of Parma, Parma, Italy
    Melanoma Res 13:73-9. 2003
    ....
  31. ncbi request reprint Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?
    V Gebbia
    Department of Experimental Oncology and Clinical Applications University of Palermo, and La Maddalena Clinic for Cancer, Palermo, Italy
    Ann Oncol 17:ii83-87. 2006
  32. ncbi request reprint A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy
    V Gebbia
    Service and Chair of Chemotherapy, Policlinico, University of Palermo, Italy
    Anticancer Res 14:731-4. 1994
    ..Similar results were achieved for fungal infections. Tolerance to thymopentin was excellent, while less than 9% of patients on G-CSF treatment complained of mild nausea and generalized bone pain...
  33. ncbi request reprint A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma
    A Callari
    Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
    Acta Oncol 33:925-9. 1994
    ..Results of the present and similar studies may, however, be useful for planning of neoadjuvant or adjuvant trials with curative intent...
  34. ncbi request reprint Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach
    V Gebbia
    Chair and Service of Chemotherapy, Institute of Pharmacology, Palermo, Italy
    J Chemother 6:147-51. 1994
    ..Despite the use of epidoxorubicin 75 mg/m2, the 26.4% (95% confidence limits 16-36%) objective response rate is not satisfactory. Evaluation of more aggressive protocols is strongly recommended within the limits of controlled trials...
  35. ncbi request reprint 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study
    S Palmeri
    Section of Clinical Oncology, University of Palermo, Italy
    J Chemother 2:327-30. 1990
    ..The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU. At this dose level all patients required dose reduction due to fatigue, fever, myalgia and severe reduction of performance status...
  36. ncbi request reprint Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study
    C Gridelli
    Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy
    Anticancer Res 21:4179-83. 2001
    ..c. days 6 to 15) administered every 3 weeks for 4 cycles and subsequent chest irradiation (50 Gy) + daily carboplatin (25 mg/m2) in the first-line treatment of adults affected by limited small cell lung cancer (SCLC)...
  37. ncbi request reprint Mental nerve invasion by basal cell carcinoma of the chin: a case report
    C Di Gregorio
    Institute of Pathology, Palermo, Italy
    Anticancer Res 18:4723-6. 1998
    ..This report stresses the importance of a correct follow-up and an accurate clinical staging in order to identifying clinical signs highly suspicious for neoplastic perineural infiltration...
  38. ncbi request reprint A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma
    V Gebbia
    Service of Chemotherapy, University of Palermo, Italy
    J Chemother 5:186-90. 1993
    ..Further studies are required to establish if the increase in dose-intensity allowed by G-CSF treatment may positively influence the outcome of cancer patients...
  39. pmc Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer
    V Gebbia
    Service of Chemotherapy, University of Palermo, Italy
    Br J Cancer 73:1576-80. 1996
    ..Data on body weight suggest that after 2 weeks' therapy MA could be stopped or its dosage tailored to patients' needs since the majority of patients respond after only 15 days of MA...
  40. ncbi request reprint The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro
    V Gebbia
    Section of Oncology, University of Palermo, Italy
    Tumori 78:167-71. 1992
    ..In conclusion, these data suggest that bryostatin-1 is a potent antileukemic agent in vitro that may be potentially useful for clinical studies...